Immunocore says TEBE-AM trial hit target enrollment
Immunocore announced achievement of target enrollment in the registrational TEBE-AM trial of KIMMTRAK (tebentafusp) in previously treated advanced melanoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.